Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai – 400063 India

Tel. : (91-22) 43244324 / 1234

Fax.: (91-22) 43244343

CIN: L24230GJ1993PLC019050, www.sunpharma.com



December 8, 2016

National Stock Exchange of India Ltd, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

NSE Code – SUNPHARMA

BSE Ltd, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001. BSE Code- 524715

Sub: Update on USFDA Inspection for Halol facility

Dear Sirs,

The USFDA inspected the Company's Halol facility in Gujarat, India from November 17, 2016 through December 1, 2016. At the conclusion of the inspection, the USFDA issued a Form-483, citing nine inspectional observations. None of those observations were characterized by the USFDA as repeat observations. The Company is preparing its responses to the observations, which will be submitted to USFDA within 15 business days of receipt of the Form-483. The Company intends to implement promptly any corrective actions and improvements that may be necessary as a result of the observations and to continue to work cooperatively with USFDA.

This is for your information and record.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,

Ashok I Bhuta
Compliance Officer

Registered Office: SPARC, Tandalja, Vadodara – 390 020. India